Today: The Medivation’s (MDVN) “Hold” Rating Reaffirmed at BMO Capital Markets

The Medivation’s (MDVN) “Hold” Rating Reaffirmed at BMO Capital Markets

Medivation Inc. (NASDAQ:MDVN)‘s stock had its “hold” rating reiterated by BMO Capital Markets in a research report issued on Sunday.

Several other equities research analysts also recently weighed in on the stock. Cowen and Company reissued a “hold” rating on shares of Medivation in a research report on Wednesday, September 28th. Canaccord Genuity reaffirmed a “buy” rating on shares of Medivation in a research report on Wednesday, September 28th. SunTrust Banks Inc. reaffirmed a “neutral” rating on shares of Medivation in a research report on Wednesday, September 14th. Vetr raised shares of Medivation from a “sell” rating to a “hold” rating and set a $79.09 target price for the company in a research report on Tuesday, August 23rd. Finally, Maxim Group set a $76.00 target price on shares of Medivation and gave the stock a “buy” rating in a research report on Monday, August 22nd. One research analyst has rated the stock with a sell rating, eighteen have given a hold rating and four have issued a buy rating to the company’s stock. Medivation presently has an average rating of “Hold” and an average price target of $73.80.

Medivation (NASDAQ:MDVN) remained flat at $81.44 during midday trading on Friday. The company’s 50 day moving average is $77.41 and its 200-day moving average is $61.39. Medivation has a 12 month low of $26.41 and a 12 month high of $81.48.

10/09/medivations-mdvn-hold-rating-reaffirmed-at-bmo-capital-markets.html

Medivation (NASDAQ:MDVN) last announced its quarterly earnings results on Tuesday, August 9th. The biopharmaceutical company reported $0.29 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.27 by $0.02. The company earned $206 million during the quarter, compared to the consensus estimate of $214.52 million. Medivation had a negative net margin of 17.24% and a positive return on equity of 17.57%. The firm’s quarterly revenue was up 17.4% compared to the same quarter last year. During the same quarter last year, the firm earned $0.58 earnings per share. Analysts forecast that Medivation will post $1.27 EPS for the current year.

Several hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. increased its position in shares of Medivation by 3.2% in the second quarter. Vanguard Group Inc. now owns 12,067,939 shares of the biopharmaceutical company’s stock valued at $727,697,000 after buying an additional 370,888 shares during the last quarter. BlackRock Institutional Trust Company N.A. increased its position in shares of Medivation by 0.7% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 3,940,666 shares of the biopharmaceutical company’s stock valued at $237,622,000 after buying an additional 28,865 shares during the last quarter. BlackRock Fund Advisors increased its position in shares of Medivation by 1.7% in the second quarter. BlackRock Fund Advisors now owns 3,682,828 shares of the biopharmaceutical company’s stock valued at $222,075,000 after buying an additional 62,931 shares during the last quarter. State Street Corp increased its position in shares of Medivation by 7.5% in the first quarter. State Street Corp now owns 3,680,057 shares of the biopharmaceutical company’s stock valued at $169,211,000 after buying an additional 258,206 shares during the last quarter. Finally, Janus Capital Management LLC increased its position in shares of Medivation by 1.0% in the second quarter. Janus Capital Management LLC now owns 3,579,877 shares of the biopharmaceutical company’s stock valued at $215,865,000 after buying an additional 35,986 shares during the last quarter. Hedge funds and other institutional investors own 87.55% of the company’s stock.

Medivation Company Profile

Related posts

Leave a Comment